Blood cancers

Consensus on MRD in CLL steps it closer to routine clinical practice

Measurable residual disease (MRD; also known as minimal residual disease) assessment and status currently has no clear role in routine clinical practice but watch this space. Writing in Hematology and Oncology Clinics of North America, Melbourne’s Professor John Seymour and international colleagues questioned whether undetectable MRD (U-MRD) should be the goal of CLL therapy. They ...

Already a member?

Login to keep reading.

© 2021 the limbic